financetom
Business
financetom
/
Business
/
Update: Market Chatter: Nvidia Under Scrutiny by Europe Regulators for Bundling GPU, Networking Hardware
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Market Chatter: Nvidia Under Scrutiny by Europe Regulators for Bundling GPU, Networking Hardware
Dec 6, 2024 8:58 AM

11:37 AM EST, 12/06/2024 (MT Newswires) -- (Updates with Nvidia's ( NVDA ) response in the sixth paragraph.)

Nvidia's ( NVDA ) customers and rivals are being questioned by Europe's anti-monopoly watchdog about whether the chipmaker is bundling its products in a way that gives it an unfair advantage and strengthens its near-monopoly market position, Reuters reported Friday, citing people with knowledge of the matter.

The European Commission has sent out questionnaires to determine whether Nvidia's ( NVDA ) graphics processing unit products are commercially and technically tied, the report said.

Antitrust regulators are looking into whether Nvidia ( NVDA ) requires graphics processing unit customers to also buy networking equipment, the report said.

The probe is separate from another one looking into Nvidia's ( NVDA ) proposed acquisition of Run:ai.

The European Commission declined to comment to MT Newswires.

"Our products are best-in-class and able to stand on their own," an Nvidia ( NVDA ) spokesperson said in an emailed response to MT Newswires. "We support open industry standards, enabling our partners and customers to use our products in a wide variety of configurations and system designs."

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 142.43, Change: -2.63, Percent Change: -1.81

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Target Plunges 21% While Williams-Sonoma Soars 27% On Same Day
Target Plunges 21% While Williams-Sonoma Soars 27% On Same Day
Nov 20, 2024
Investors were treated to quite the pair trade on Wednesday when shares of big box retailer Target Corp ( TGT ) sunk while shares of home furnishing retailer Williams-Sonoma, Inc. ( WSM ) rocketed off earnings. The two stocks were the biggest movers of the day, according to Benzinga Pro. Price Action: Target’s stock closed the day at $121.72, down...
Update: Reddit Users Report Possible Outages, Tracking Website Says
Update: Reddit Users Report Possible Outages, Tracking Website Says
Nov 20, 2024
05:46 PM EST, 11/20/2024 (MT Newswires) -- (Adds company's response, other details throughout.) Reddit ( RDDT ) late Wednesday said it was returning to normal operations after a bug in a recent software update resulted in outages for some users of the social media company earlier this afternoon. Downdetector, which monitors outages and user problems on websites operated by companies...
Kura Oncology, Kyowa Kirin to Jointly Develop of Blood Cancer Drug
Kura Oncology, Kyowa Kirin to Jointly Develop of Blood Cancer Drug
Nov 20, 2024
05:46 PM EST, 11/20/2024 (MT Newswires) -- Kura Oncology ( KURA ) and Kyowa Kirin said Wednesday that will develop and commercialize ziftomenib for the treatment of patients with blood cancer. Kura will receive $330 million in upfront payment and up to $420 million in near-term milestone payments, according to the companies. It will also be eligible for $741 million...
Nurix Therapeutics Gets Priority Medicines Label for NX-5948 in Europe
Nurix Therapeutics Gets Priority Medicines Label for NX-5948 in Europe
Nov 20, 2024
05:45 PM EST, 11/20/2024 (MT Newswires) -- Nurix Therapeutics ( NRIX ) said Wednesday it received PRIME designation from the European Medicines Agency for NX-5948 to treat adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The PRIME, or priority medicines, designation follows encouraging safety and efficacy data from an ongoing phase 1 trial, the company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved